Privacy Policy
Signals Blog

Contributors

Categories

Cell Therapy Deal Review: September

by | Oct 20, 2015

. Welcome to your Cell Therapy Deal Review for the month of September. Aduro Biotech went the way of Juno and Kite and bought an antibody discovery platform. Intrexon and ZIOPHARM entered into an agreement to develop a novel Treg-based immunotherapy for GvHD. Kite...

Cell Therapy Deal Review: August

by | Sep 30, 2015

. Welcome to your cell therapy deal review for the month of August. Synthetic biology giant Intrexon closed a large financing; Immune Design announced a collaboration to pair its viral-based immunotherapy platform with a checkpoint inhibitor; and, NantKwest received a...

Update from the Clinic: August

by | Sep 29, 2015

. Welcome to your Update from the Clinic for the month of August. The adult stem cell community enjoyed a much needed confidence boost after TiGenix announced its Phase 3 trial hit its primary endpoint. Northwest confirmed its Phase 3 trial of DCVax in glioblastoma is...

The tiny fingers that touch stem cells

by | Sep 22, 2015

. I was reading Nature the other day and came across a neat article from Yukikio Yamashita’s group at the University of Michigan entitled Nanotubes mediate niche–stem-cell signalling in the Drosophila testis. It may not sound interesting to our average reader, but the...

The waiting game: First human iPSC clinical trial on hold

by | Sep 1, 2015

. Nicole Forgione is a post-doctoral fellow working in the Fehlings group at the Toronto Western Research Institute. Currently she holds a Toronto Western Research Institute Fellowship to support her work on cell-based regenerative therapies for traumatic spinal cord...